You are here

Home » Content

Organ Redlerine Işık Tutabilecek Nakiller: Kompozit Doku Nakilleri

Transplantations which might Shed Light on Organ Rejections: Composite Tissue Transplantations

Journal Name:

  • Akdeniz Tıp Dergisi

Publication Year:

  • 2015
DOI: 
10.17954/amj.2015.12

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Transplantation is used as a cure for the end-stage renal and liver failure that may be fatal. Although transplantation is an option for the patient to cling to life, there is a risk of rejection of the transplanted organ. Extensive research has been conducted on this subject as organ rejections are a major problem of transplantation. The number of composite tissue transplants, which are performed to improve the patient’s quality of life, has increased during the last decade. The frequency of chronic rejection in composite tissue transplantation with this method has been observed to be less than that of solid organ transplantation. A lower frequency of chronic rejection is intriguing given the fact that more immunogenic tissues are transplanted in composite tissue transplantation. The elucidation of molecular and immunological mechanisms underlying this “rare rejection” phenomenon is of utmost importance. The scientifi c community might make signifi cant progress in the early diagnosis and prevention of solid organ rejections data from future studies.
Bookmark/Search this post with
Abstract (Original Language): 
Son dönem böbrek ve karaciğer yetmezliği gibi ölümle sonuçlanabilecek hastalıkların kesin tedavisi olarak organ nakli (Transplantasyon) uygulanmaktadır. Organ nakilleri her ne kadar hastayı yaşama bağlayan bir yöntem olsa da; nakledilen organların reddedilme riski mevcuttur. Organ Rejeksiyonlarının organ nakillerinin önemli bir dezavantajı olmasından dolayı üzerinde yapılan araştırmaların sayısı fazladır. Son on yılda hastanın yaşam kalitesini artırmak için uygulanan kompozit doku nakillerinin sayısı artmıştır. Yapılan nakil sayılarının artması sonucu, kompozit doku nakillerinde gelişen kronik rejeksiyon sıklığının solid organ naklindekinden daha az olduğu görülmüştür. Daha immünolojik özellikteki dokuların nakledilmesine rağmen kronik rejeksiyon görülme sıklığının az olması merak uyandırıcıdır. Bu seyrek görülen rejeksiyonların altında yatan moleküler ve immünolojik nedenlerin aydınlatılması büyük önem taşımaktadır. Elde edilecek bilgiler doğrultusunda solid organ nakillerinde de oluşacak rejeksiyonların erken tanısı ve de önlenmesinde bilim camiası önemli bir ilerleme gösterecektir.
FULL TEXT (PDF): 
PDF icon arastirmax-organ-redlerine-isik-tutabilecek-nakiller-kompozit-doku-nakilleri.pdf
  • 2
77
84
  • Turkish

REFERENCES

References: 

1. Josien R, Pannetier C, Douillard P, Cantarovich D,
Menoret S, Bugeon L, Kourilsky P, Soulillou JP, Cuturi MC.
Graft-infi ltrating T helper cells, CD45RC phenotype, and
Th1/Th2-related cytokines in donor-specifi c transfusioninduced
tolerance in adult rats. Transplantation 1995; 60:
1131-9.
2. Horak I, Lohler J, Ma A. Smith KA. Interleukin-2
defi cient mice: a new model to study autoimmunity and
self-tolerance. Immunol Rev 1995; 148:35-44.
3. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas
AK. Biochemical mechanisms of IL-2-regulated Fasmediated
T cell apoptosis. Immunity 1998; 8: 615-23.
4. Irmler M, Thome M, Hahne M, Schneider P, Hofmann,
K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann
C, Rimoldi D, French LE, Tschopp J. Inhibition of death
receptor signals by cellular FLIP. Nature 1997; 388:190-5.
5. Li X. The common gammac-cytokines and transplantation
tolerance. Cell Mol Immunol 2004; 1:167-72.
6. McLaughlin PJ, Aikawa A, Davies HM, Ward RG, Bakran
A, Sells RA, Johnson PM. Evaluation of sequential plasma
and urinary tumor necrosis factor alpha levels in renal
allograft recipients. Transplantation 1991; 51:1225-9.
7. Deng MC, Plenz G, Labarrere C, Marboe C, Baba HA,
Erre M, Itescu, S. The role of IL6 cytokines in acute
cardiac allograft rejection. Transpl Immunol 2002; 9:115-
20.
8. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay
D, Koss KE, Geehan CS, Luster AD, Sayegh MH, Briscoe
DM. Proinfl ammatory functions of vascular endothelial
growth factor in alloimmunity. J Clin Invest 2003; 112,
1655-65.
9. Luscinskas FW, Cybulsky MI, Kiely JM, Peckins CS,
Davis VM, Gimbrone MA Jr. Cytokine-activated
human endothelial monolayers support enhanced
neutrophil transmigration via a mechanism involving
both endothelial-leukocyte adhesion molecule-1 and
intercellular adhesion molecule-1. J Immunol 1991; 146:
1617-25.
10. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and
tumor necrosis factor alpha are costimulators of
interferon gamma production by natural killer cells in
severe combined immunodefi ciency mice with listeriosis,
and interleukin 10 is a physiologic antagonist. Proc Natl
Acad Sci USA 1993; 90: 3725-9.
11. Chang CH, Furue M, Tamaki K. Selective regulation
of ICAM-1 and major histocompatibility complex class
I and II molecule expression on epidermal Langerhans
cells by some of the cytokines released by keratinocytes
and T cells. Eur J Immunol 1994; 24: 2889-95.
12. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo
A, Domenig C, Habicht A, Najafi an N, Yagita H, Azuma
M, Turka LA, Sayegh MH. Role of the programmed
death-1 pathway in regulation of alloimmune responses
in vivo. J Immunol 2005; 174:3408-15.
13. Yamada J, Yoshida M, Taylor AW, Streilein JW. Mice with
Th2-biased immune systems accept orthotopic corneal
allografts placed in “high risk” eyes. J Immunol 1999; 162:
5247-55.
14. Niederkorn JY. Immune mechanisms of corneal allograft
rejection. Curr Eye Res 2007; 32:1005-16.
15. Hargrave S, Chu Y, Mendelblatt D, Mayhew E,
Niederkorn J. Preliminary fi ndings in corneal allograft
rejection in patients with keratoconus. Am J Ophthalmol
2003; 135: 452-60.
83
Organ Redlerine Işık Tutabilecek Nakiller: Kompozit Doku Nakilleri
Akd Tıp D / Akd Med J / 2015; 2: 77-84
16. Matzinger P. Friendly and dangerous signals: Is the tissue
in control? Nat Immunol 2007; 8: 11-3.
17. Schwartz RH. Natural regulatory T cells and selftolerance.
Nat Immunol 2005; 6:327-30.
18. Monk NJ, Hargreaves RE, Simpson E, Dyson JP, Jurcevic
S. Transplant tolerance: Models, concepts and facts. J Mol
Med (Berl) 2006; 84, 295-304.
19. Kingsley CI, Karim M, Bushell AR, Wood KJ.
CD25+CD4+ regulatory T cells prevent graft rejection:
CTLA-4- and IL-10-dependent immunoregulation of
alloresponses. J Immunol 2002; 168:1080-6.
20. Onodera K, Hancock WW, Graser E, Lehmann M,
Sayegh MH, Strom TB, Volk HD, Kupiec-Weglinski JW.
Type 2 helper T cell-type cytokines and the development
of “infectious” tolerance in rat cardiac allograft recipients.
J Immunol 1997; 158:1572-81.
21. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z,
Nunez G, Tang A, Sayegh M, Hancock WW, Strom
TB, Turka LA. Requirement for T-cell apoptosis in the
induction of peripheral transplantation tolerance. Nat
Med 1999; 5:1303-7.
22. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired
alloantigen-mediated T cell apoptosis and failure to
induce long-term allograft survival in IL-2-defi cient mice.
J Immunol 1998; 161: 1659-63.
23. Bushell A, Niimi M, Morris PJ, Wood KJ. Evidence for
immune regulation in the induction of transplantation
tolerance: A conditional but limited role for IL-4. J
Immunol 1999; 162: 1359-66.
24. Li XC, Ima A, Li Y, Zheng XX, Malek TR, Strom TB.
Blocking the common gamma-chain of cytokine receptors
induces T cell apoptosis and long-term islet allograft
survival. J Immunol 2000; 164: 1193-9.
25. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW,
Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J,
Strom TB, Zheng XX, Noelle RJ. Mast cells are essential
intermediaries in regulatory T-cell tolerance. Nature
2006; 442:997-1002.
26. Kielar ML, John R, Bennett M, Richardson JA, Shelton
JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B,
Nagami GT, Lu CY. Maladaptive role of IL-6 in ischemic
acute renal failure. J Am Soc Nephrol 2005; 16:3315-25.
27. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M,
Webb TJ, Baldridge LA, Heidler KM, Cummings OW,
Fujisawa T, Blum JS, Brand DD, Wilkes DS. Anti-type
V collagen lymphocytes that express IL-17 and IL-23
induce rejection pathology in fresh and well-healed lung
transplants. Am J Transplant 2006; 6:724-35.
28. Chen Y, Wood KJ. Interleukin-23 and TH17 cells in
transplantation immunity: Does 23+17 equal rejection?
Transplantation 2007; 84:1071-4.
29. Li J, Simeoni E, Fleury S, Dudler J, Fiorini E, Kappenberger
L, von Segesser LK, Vassalli G. Gene transfer of soluble
interleukin-17 receptor prolongs cardiac allograft survival
in a rat model. Eur J Cardiothorac Surg 2006; 29:779-83.
30. Tang JL, Subbotin VM, Antonysamy MA, Troutt AB, Rao
AS, Thomson AW. Interleukin-17 antagonism inhibits
acute but not chronic vascular rejection. Transplantation
2001; 72:348-50.
31. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S,
Troutt AB, Thomson AW. Evidence for a role of IL-17 in
organ allograft rejection: IL-17 promotes the functional
differentiation of dendritic cell progenitors. J Immunol
1999; 162:577-84.
32. Cendales LC, Kanitakis J, Schneeberger S, Burns C, Ruiz
P, Landin L, Remmelink M, Hewitt CW, Landgren T,
Lyons B, Drachenberg CB, Solez K, Kirk AD, Kleiner
DE, Racusen, L. The Banff 2007 working classifi cation of
skin-containing composite tissue allograft pathology. Am J
Transplant 2008; 8:1396-400.
33. Kaufman CL, Ouseph R, Blair B, Kutz JE, Tsai TM,
Scheker LR, Tien HY, Moreno R, Ozyurekoglu T,
Banegas R, Murphy E, Burns CB, Zaring R, Cook
DF, Marvin MR. Graft vasculopathy in clinical hand
transplantation. Am J Transplant 2012; 12:1004-16.
34. Kaufman CL, Ouseph R, Marvin MR, Manon-Matos Y,
Blair B, Kutz JE. Monitoring and long-term outcomes in
vascularized composite allotransplantation. Curr Opin
Organ Transplant 2013; 18:652-8.
35. Kanitakis J, Morelon E, Petruzzo P, Badet L, Dubernard
JM. Self-renewal capacity of human epidermal
Langerhans cells: Observations made on a composite
tissue allograft. Exp Dermatol 2011; 20:145-6.
36. Kanitakis J, Petruzzo P, Dubernard JM. Turnover
of epidermal Langerhans’ cells. N Engl J Med2004;
351:2661-2.
37. Eljaafari A, Badet L, Kanitakis J, Ferrand C, Farre A,
Petruzzo P, Morelon E, Dubosson M, Tiberghien P,
Dubois V, Martin X, Miossec P, Dubernard JM. Isolation
of regulatory T cells in the skin of a human hand-allograft,
up to six years posttransplantation. Transplantation 2006;
82:1764-8.
38. Hautz T, Brandacher G, Zelger B, Muller HG, Lee AW,
Fuchs D, Margreiter R, Schneeberger S. Indoleamine
2,3-dioxygenase and foxp3 expression in skin rejection of
human hand allografts. Transplant Proc 2009; 41: 509-12.
39. Diefenbeck M, Nerlich A, Schneeberger S, Wagner F,
Hofmann GO. Allograft vasculopathy after allogeneic
vascularized knee transplantation. Transpl Int 2011; 24:
e1-5.
84
Ertosun MG ve ark.
Akd Tıp D / Akd Med J / 2015; 2: 77-84
40. Unadkat JV, Schneeberger S, Horibe EH, Goldbach C,
Solari MG, Washington KM, Gorantla VS, Cooper GM,
Thomson AW, Lee, WP. Composite tissue vasculopathy
and degeneration following multiple episodes of acute
rejection in reconstructive transplantation. Am J
Transplant 2010; 10:251-61.
41. Unadkat JV, Schneeberger S, Goldbach C, Solari MG,
Washington KM, Afrooz PN, Pulikkottil BJ, Zheng XX,
Lee WP. Investigation of antibody-mediated rejection
in composite tissue allotransplantation in a rat limb
transplant model. Transplant Proc 2009; 41:542-5.
42. Hewitt CW, Black KS, Henson LE, Achauer BM,
Nguyen JH. Lymphocyte chimerism in a full allogeneic
composite tissue (rat-limb) allograft model prolonged with
cyclosporine. Transplant Proc 1988; 20:272-8.
43. Granger DK, Briedenbach WC, Pidwell DJ, Jones
JW, Baxter-Lowe LA, Kaufman CL. Lack of donor
hyporesponsiveness and donor chimerism after clinical
transplantation of the hand. Transplantation 2002;
74:1624-30.
44. Mundinger GS, Munivenkatappa R, Drachenberg CB,
Ha JS, Vaca EE, Shipley ST, Papadimitriou JC, Bartlett
ST, Rodriguez ED, Barth RN. Histopathology of chronic
rejection in a nonhuman primate model of vascularized
composite allotransplantation. Transplantation 2013;
95:1204-10.
45. Mundinger GS, Drachenberg CB. Chronic rejection
in vascularized composite allografts. Curr Opin Organ
Transplant 2014; 19:309-14.
46. Meuli-Simmen C, Eiman T, Alpert BS, Meyer VE,
Buncke GM, Buncke HJ. Fibromuscular proliferation
in fi nger arteries after hand replantation: a case report.
Microsurgery 1996; 17:551-4.

Thank you for copying data from http://www.arastirmax.com